Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-25-001982·BIOTECHNOLOGY VALUE FUND L P
Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock, $0.00001 par value per share · CUSIP: 23284F105
Event date: 2025-07-03
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 3,074,013.00 · Class: 1.9%
- BVF I GP LLC
Shares: 3,074,013.00 · Class: 1.9%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 2,351,446.00 · Class: 1.5%
- BVF II GP LLC
Shares: 2,351,446.00 · Class: 1.5%
- Biotechnology Value Trading Fund OS LP
Shares: 270,616.00 · Class: 0.2%
- BVF Partners OS Ltd.
Shares: 270,616.00 · Class: 0.2%
- BVF GP HOLDINGS LLC
Shares: 5,425,459.00 · Class: 3.3%
- BVF PARTNERS L P/IL
Shares: 5,769,231.00 · Class: 3.5%
- BVF INC/IL
Shares: 5,769,231.00 · Class: 3.5%
- LAMPERT MARK N
Shares: 5,769,231.00 · Class: 3.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-001982
- Form type
- SCHEDULE 13G/A
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Jul 09, 2025
- Reporting period
- Jul 03, 2025
- Description
- Schedule 13G beneficial ownership